Literature DB >> 12742154

Blastoid mantle cell lymphoma: evidence for nonrandom cytogenetic abnormalities additional to t(11;14) and generation of a mouse model.

R M'kacher1, F Farace, A Bennaceur-Griscelli, D Violot, B Clausse, J Dossou, A Valent, C Parmentier, V Ribrag, J Bosq, P Carde, A G Turhan, A Bernheim.   

Abstract

Mantle cell lymphoma (MCL) is characterized by the t(11;14)(q13;q32), which is associated with cyclin D1 hyperexpression and a poor prognosis. MCL cases have been shown to progress to a more aggressive disease but the molecular events responsible of this phenomenon have not been determined. We have established two cell lines from the pleural effusions of two patients with MCL that we have used for further cytogenetic characterization to better define the incidence and nature of secondary chromosome abnormalities using multicolor fluorescence in situ hybridization, whole chromosome paint, and specific probes. Both cell lines grew independently without growth factors. Using CCND1/IGH-specific probes, patient UPN1 was found to have a masked t(11;14). Numerous and complex chromosomal abnormalities were found in both cell lines affecting chromosomes 2, 8, 13, 18, 22, X, and Y. These abnormalities included 8p losses, suggesting the presence of an anti-oncogene in this region, rearrangements of 8q24, MYC gene, and translocations involving 8, X, and Y chromosomes, which might be significant in the pathogenesis of MCL progression. The use of the cell lines (UPN1) allowed us to generate a mouse model of human MCL, mimicking a disseminated lymphoma and leading to the death of the animals in 4 weeks. This blastoid MCL model could be of major interest to determine molecular events involved in MCL progression, allowing isolation of involved genes and their functional characterization, and to study the effects of new chemotherapy regimens in mouse models.

Entities:  

Mesh:

Year:  2003        PMID: 12742154     DOI: 10.1016/s0165-4608(02)00823-3

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  10 in total

1.  Parallel gene expression profiling of mantle cell lymphoma - how do we transform 'omics data into clinical practice.

Authors:  Ek Sara; Carl Ak Borrebaeck
Journal:  Curr Genomics       Date:  2007-05       Impact factor: 2.236

2.  FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.

Authors:  Lapo Alinari; Emilia Mahoney; John Patton; Xiaoli Zhang; Lenguyen Huynh; Christian T Earl; Rajeswaran Mani; Yicheng Mao; Bo Yu; Carl Quinion; William H Towns; Ching-Shih Chen; David M Goldenberg; Kristie A Blum; John C Byrd; Natarajan Muthusamy; Mette Praetorius-Ibba; Robert A Baiocchi
Journal:  Blood       Date:  2011-10-31       Impact factor: 22.113

3.  Development of a murine model for blastoid variant mantle-cell lymphoma.

Authors:  Richard J Ford; Long Shen; Yen Chiu Lin-Lee; Lan V Pham; Asha Multani; Hai-Jun Zhou; Archito T Tamayo; ChongJie Zhang; Lesleyann Hawthorn; John K Cowell; Julian L Ambrus
Journal:  Blood       Date:  2007-02-20       Impact factor: 22.113

4.  CD5-negative blastoid variant mantle cell lymphoma with complex CCND1/IGH and MYC aberrations.

Authors:  Yoonmi Seok; Juwon Kim; Jong Rak Choi; Yu Ri Kim; Seo-Jin Park; Sue Jung Kim; Jaewoo Song; Kyung-A Lee
Journal:  Ann Lab Med       Date:  2011-12-20       Impact factor: 3.464

5.  miR-1204 targets VDR to promotes epithelial-mesenchymal transition and metastasis in breast cancer.

Authors:  Xiaoyan Liu; Lei Bi; Qin Wang; Mingxin Wen; Ce Li; Yidan Ren; Qinlian Jiao; Jian-Hua Mao; Chuanxin Wang; Guangwei Wei; Yunshan Wang
Journal:  Oncogene       Date:  2018-03-20       Impact factor: 9.867

6.  Cyclin D1 depletion induces DNA damage in mantle cell lymphoma lines.

Authors:  Suchismita Mohanty; Atish Mohanty; Natalie Sandoval; Thai Tran; Victoria Bedell; Jun Wu; Anna Scuto; Joyce Murata-Collins; Dennis D Weisenburger; Vu N Ngo
Journal:  Leuk Lymphoma       Date:  2016-06-24

7.  Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas.

Authors:  Delphine Rolland; Venkatesha Basrur; Kevin Conlon; Thomas Wolfe; Damian Fermin; Alexey I Nesvizhskii; Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  Am J Pathol       Date:  2014-03-22       Impact factor: 4.307

8.  Telomere and Centromere Staining Followed by M-FISH Improves Diagnosis of Chromosomal Instability and Its Clinical Utility.

Authors:  Radhia M'kacher; Bruno Colicchio; Claire Borie; Steffen Junker; Valentine Marquet; Leonhard Heidingsfelder; Kevin Soehnlen; Wala Najar; William M Hempel; Noufissa Oudrhiri; Nadège Wilhelm-Murer; Marguerite Miguet; Micheline Arnoux; Catherine Ferrapie; Wendy Kerbrat; Andreas Plesch; Alain Dieterlen; Theodore Girinsky; Philippe Voisin; Georges Deschenes; Anne-Claude Tabet; Catherine Yardin; Annelise Bennaceur-Griscelli; Michael Fenech; Patrice Carde; Eric Jeandidier
Journal:  Genes (Basel)       Date:  2020-04-27       Impact factor: 4.096

9.  CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma.

Authors:  Atish Mohanty; Natalie Sandoval; Manasi Das; Raju Pillai; Lu Chen; Robert W Chen; Hesham M Amin; Michael Wang; Guido Marcucci; Dennis D Weisenburger; Steven T Rosen; Lan V Pham; Vu N Ngo
Journal:  Oncotarget       Date:  2016-11-08

Review 10.  Chromosomal Instability in Hodgkin Lymphoma: An In-Depth Review and Perspectives.

Authors:  Corina Cuceu; William M Hempel; Laure Sabatier; Jacques Bosq; Patrice Carde; Radhia M'kacher
Journal:  Cancers (Basel)       Date:  2018-03-26       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.